Mazdutide

Mazdutide is a peptide that acts at receptors for glucagon-like peptide-1 (GLP-1) and glucagon. It has been investigated for effects on body weight and glucose metabolism, including potential applications in obesity and type 2 diabetes.

GLP-1 signaling participates in appetite control, glucose-dependent insulin secretion, and regulation of stomach emptying. Glucagon signaling contributes to fuel mobilization and glucose balance, providing a distinct metabolic pathway for investigation alongside GLP-1 activity.

Research on mazdutide examines how combined GLP-1 receptor and glucagon receptor activity influences food intake and metabolic regulation. Proposed mechanisms include changes in satiety signaling and lipid utilization, although the supplied notes do not establish the relative contribution of each pathway.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents mazdutide as a candidate for research into excess body weight and metabolic dysfunction. It attributes possible reductions in body weight and improvements in insulin responsiveness to its dual-receptor activity. The guide also characterizes tolerability favorably while identifying digestive symptoms and potential pancreatic or gallbladder concerns.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The notes provide no identifiable studies or trial details with which to assess the magnitude, durability, or certainty of the reported benefits. They also do not distinguish clearly between mazdutide-specific safety findings and concerns inferred from related compounds.

The guide lists nausea, vomiting, loose stools, and fullness or abdominal bloating associated with slower stomach emptying as possible adverse effects. It also raises pancreatic inflammation and gallbladder disorders as potential concerns, without establishing their frequency or causal relationship to mazdutide. Safety data available in the supplied material are limited, and this summary is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Mazdutide GLP-1 glucagon dual agonist”
• “Mazdutide appetite suppression and weight loss”
• “Mazdutide clinical trials”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN